These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 8772643

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
    DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ.
    Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
    Denardo GL, Denardo SJ, Kukis DL, O'Donnell RT, Shen S, Goldstein DS, Kroger LA, Salako Q, Denardo DA, Mirick GR, Mausner LF, Srivastava SC, Meares CF.
    Anticancer Res; 1998 Mar; 18(4B):2779-88. PubMed ID: 9713461
    [Abstract] [Full Text] [Related]

  • 5. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
    O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR, DeNardo SJ.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
    [Abstract] [Full Text] [Related]

  • 6. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
    O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ.
    J Nucl Med; 1999 Dec; 40(12):2014-20. PubMed ID: 10616879
    [Abstract] [Full Text] [Related]

  • 7. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL.
    Anticancer Res; 2000 Dec; 20(5C):3647-55. PubMed ID: 11268433
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2.
    DeNardo GL, Kukis DL, DeNardo SJ, Shen S, Mausner LF, O'Donnell RT, Lamborn KR, Meyers FJ, Srivastava SC, Miers LA.
    Cancer; 1997 Dec 15; 80(12 Suppl):2576-82. PubMed ID: 9406712
    [Abstract] [Full Text] [Related]

  • 9. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.
    Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, Mack PC, Leshchinsky T, DeNardo SJ.
    Cancer Biother Radiopharm; 2001 Jun 15; 16(3):213-25. PubMed ID: 11471486
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
    DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, Goldstein DS, Mirick GR, Salako Q, Mausner LF, Srivastava SC, Meares CF.
    J Nucl Med; 1999 Feb 15; 40(2):302-10. PubMed ID: 10025839
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.
    Kroger LA, DeNardo SJ, DeNardo GL, Xiong CY, Winthrop MD, Gumerlock PH.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3010s-3014s. PubMed ID: 10541336
    [Abstract] [Full Text] [Related]

  • 16. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.
    Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, Greiner DP, Meares CF.
    Cancer Res; 1995 Feb 15; 55(4):878-84. PubMed ID: 7850803
    [Abstract] [Full Text] [Related]

  • 17. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates.
    Kukis DL, Diril H, Greiner DP, DeNardo SJ, DeNardo GL, Salako QA, Meares CF.
    Cancer; 1994 Feb 01; 73(3 Suppl):779-86. PubMed ID: 8306260
    [Abstract] [Full Text] [Related]

  • 18. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF.
    J Nucl Med; 1998 Dec 01; 39(12):2105-10. PubMed ID: 9867151
    [Abstract] [Full Text] [Related]

  • 19. Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.
    Connett JM, Anderson CJ, Guo LW, Schwarz SW, Zinn KR, Rogers BE, Siegel BA, Philpott GW, Welch MJ.
    Proc Natl Acad Sci U S A; 1996 Jun 25; 93(13):6814-8. PubMed ID: 8692901
    [Abstract] [Full Text] [Related]

  • 20. Conjugation of monoclonal antibodies with TETA using activated esters: biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3.
    Lewis MR, Boswell CA, Laforest R, Buettner TL, Ye D, Connett JM, Anderson CJ.
    Cancer Biother Radiopharm; 2001 Dec 25; 16(6):483-94. PubMed ID: 11789025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.